Dare Bioscience, Inc. announced positive findings from the Phase 2b RESPOND study for Sildenafil Cream as a potential treatment for female sexual arousal disorder (FSAD) and female sexual interest/arousal disorder (FSIAD), supporting the advancement of the cream into a Phase 3 pivotal study.